Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
February 21, 2025 at 13:48 PM EST
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
